AU2009215436A1 - Postsynaptically targeted chemodenervation agents and their methods of use - Google Patents

Postsynaptically targeted chemodenervation agents and their methods of use Download PDF

Info

Publication number
AU2009215436A1
AU2009215436A1 AU2009215436A AU2009215436A AU2009215436A1 AU 2009215436 A1 AU2009215436 A1 AU 2009215436A1 AU 2009215436 A AU2009215436 A AU 2009215436A AU 2009215436 A AU2009215436 A AU 2009215436A AU 2009215436 A1 AU2009215436 A1 AU 2009215436A1
Authority
AU
Australia
Prior art keywords
chemodenervation
polypeptide
neurotoxin
polypeptides
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009215436A
Other languages
English (en)
Inventor
Todd Lorenz
Lars Erik Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MYOCEPT Inc
Original Assignee
MYOCEPT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MYOCEPT Inc filed Critical MYOCEPT Inc
Publication of AU2009215436A1 publication Critical patent/AU2009215436A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2009215436A 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use Abandoned AU2009215436A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6634708P 2008-02-19 2008-02-19
US61/066,347 2008-02-19
PCT/US2009/034578 WO2009105585A2 (en) 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use

Publications (1)

Publication Number Publication Date
AU2009215436A1 true AU2009215436A1 (en) 2009-08-27

Family

ID=40986187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009215436A Abandoned AU2009215436A1 (en) 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use

Country Status (9)

Country Link
US (1) US9815875B2 (enExample)
EP (1) EP2250193B1 (enExample)
JP (1) JP2011523935A (enExample)
CN (1) CN102007142A (enExample)
AU (1) AU2009215436A1 (enExample)
CA (1) CA2754352A1 (enExample)
ES (1) ES2757648T3 (enExample)
IL (1) IL207631A0 (enExample)
WO (1) WO2009105585A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
KR20120093312A (ko) * 2009-10-30 2012-08-22 바이엘 헬스케어 엘엘씨 항체 모방체 스캐폴드
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
CN103145799B (zh) * 2013-02-18 2014-04-16 大连理工大学 一组具有促进经皮和跨膜渗透作用的多肽及其应用
CN104232653B (zh) * 2014-09-19 2017-04-05 中南大学湘雅医院 重组α‑银环蛇毒素αBtx的制备方法
JP2020518653A (ja) * 2017-02-07 2020-06-25 マイオセプト インコーポレイティド 局所製剤及び方法
CN110090296A (zh) * 2018-09-21 2019-08-06 祁展楷 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用
CN118561963A (zh) 2018-10-16 2024-08-30 格罗制药公司 烟碱乙酰胆碱受体肽拮抗剂芋螺毒素组合物及相关方法
AU2019408420B2 (en) * 2018-12-21 2025-04-17 Vib Vzw Fusion protein with a toxin and scaffold protein
EP3753568A1 (en) * 2019-06-21 2020-12-23 Fastox Pharma SA Composition modulating botulinum neurotoxin effect
CN110478473B (zh) * 2019-07-14 2025-08-12 江苏毫末医药生物科技有限公司 眼镜蛇神经毒素多肽对鸦片类药品痛觉过敏和耐受的抑制及对其镇痛的协同增效作用
EP4046648A4 (en) * 2019-10-11 2023-10-18 Qi, Zhankai Application of elapidae snake postsynaptic neurotoxin monomer molecule in treatment of alzheimer's disease
EP4093378A1 (en) * 2020-01-24 2022-11-30 W.L. Gore & Associates, Inc. Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof
CN111544571A (zh) * 2020-06-02 2020-08-18 沈喆景 眼镜蛇科蛇突触后神经毒素在治疗与炎性细胞因子过度表达相关疾病的应用
CN114409757B (zh) * 2022-01-26 2023-07-18 云南南诏药业有限公司 一种蛇毒神经毒素及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
FR2762009B1 (fr) * 1997-04-10 1999-06-04 Commissariat Energie Atomique Enzymes recombinantes purifiees a activite prolylpeptidasique, leur procede de preparation et leurs applications
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7964630B2 (en) 2004-11-02 2011-06-21 Dsm Ip Assets B.V. Topical application agents against mimic and age-related wrinkles
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US7659252B2 (en) * 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof

Also Published As

Publication number Publication date
JP2011523935A (ja) 2011-08-25
ES2757648T3 (es) 2020-04-29
CA2754352A1 (en) 2009-08-27
IL207631A0 (en) 2010-12-30
EP2250193A2 (en) 2010-11-17
US20110118190A1 (en) 2011-05-19
EP2250193B1 (en) 2019-09-18
US9815875B2 (en) 2017-11-14
CN102007142A (zh) 2011-04-06
WO2009105585A3 (en) 2009-12-23
WO2009105585A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
US9815875B2 (en) Postsynaptically targeted chemodenervation agents and their methods of use
KR102240347B1 (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
EP1993589B1 (en) Treatments for neurological disorders
AU2006310577B2 (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
KR20140068148A (ko) 이질통, 통각과민증, 자발통 및 환상통의 치료
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
JP2007534746A (ja) 化学療法誘発性ニューロパシーの治療または予防のためのｉｌ−６
EP3010524A1 (en) Protamine in treatment of neuronal injuries
JP5048658B2 (ja) 神経性炎症性疾患の治療、及び／又は予防のためのｉｌ−１８ｂｐアイソフォームの使用
HK1123210A (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
AT511913A2 (de) Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted